Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says

MT Newswires Live

Jan 07

The US biotechnology sector is poised for growth in 2026, with several companies having near-term catalysts and promising clinical trial readouts that could drive momentum, BofA Securities said in a note Tuesday.

The analysts said that the Nasdaq Biotechnology Index has bounced back to 2021 levels, outperforming the broader market. Key positives include strong data releases being rewarded, ongoing mergers and acquisitions by big pharma, better access to capital, and limited impact so far from drug pricing regulations. Innovation from China and shifts in global pharma spending add further upside potential.

The analysts said they have refreshed their top picks for 2026 to include Revolution Medicines (RVMD), Regenxbio (RGNX), Krystal Biotech (KRYS), and Immatics (IMTX). "We favor companies with near-term binary catalysts with derisking data to support a positive view," they said.

BofA updated its price objectives for the top picks, raising Immatics to $17 from $14, Krystal Biotech to $272 from $255, Regenxbio to $28 from $20, and Revolution Medicines to $98 from $82.

Price: 79.86, Change: +1.53, Percent Change: +1.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601810656"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601810656\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601810656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 03:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601810656","market":"us","top_or_hot":-1,"title":"Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says","media":"MT Newswires Live","content":"<html><body><p> The US biotechnology sector is poised for growth in 2026, with several companies having near-term catalysts and promising clinical trial readouts that could drive momentum, BofA Securities said in a note Tuesday.</p><p>The analysts said that the Nasdaq Biotechnology Index has bounced back to 2021 levels, outperforming the broader market. Key positives include strong data releases being rewarded, ongoing mergers and acquisitions by big pharma, better access to capital, and limited impact so far from drug pricing regulations. Innovation from China and shifts in global pharma spending add further upside potential.</p><p>The analysts said they have refreshed their top picks for 2026 to include <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD), Regenxbio (RGNX), <a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> (KRYS), and Immatics (IMTX). \"We favor companies with near-term binary catalysts with derisking data to support a positive view,\" they said.</p><p>BofA updated its price objectives for the top picks, raising Immatics to $17 from $14, Krystal Biotech to $272 from $255, Regenxbio to $28 from $20, and Revolution Medicines to $98 from $82.</p><p>Price: 79.86, Change: +1.53, Percent Change: +1.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-07 03:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The US biotechnology sector is poised for growth in 2026, with several companies having near-term catalysts and promising clinical trial readouts that could drive momentum, BofA Securities said in a note Tuesday.</p><p>The analysts said that the Nasdaq Biotechnology Index has bounced back to 2021 levels, outperforming the broader market. Key positives include strong data releases being rewarded, ongoing mergers and acquisitions by big pharma, better access to capital, and limited impact so far from drug pricing regulations. Innovation from China and shifts in global pharma spending add further upside potential.</p><p>The analysts said they have refreshed their top picks for 2026 to include <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD), Regenxbio (RGNX), <a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> (KRYS), and Immatics (IMTX). \"We favor companies with near-term binary catalysts with derisking data to support a positive view,\" they said.</p><p>BofA updated its price objectives for the top picks, raising Immatics to $17 from $14, Krystal Biotech to $272 from $255, Regenxbio to $28 from $20, and Revolution Medicines to $98 from $82.</p><p>Price: 79.86, Change: +1.53, Percent Change: +1.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601810656","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601810656","pubTimestamp":1767728704,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The US biotechnology sector is poised for growth in 2026, with several companies having near-term catalysts and promising clinical trial readouts that could drive momentum, BofA Securities said in a note Tuesday.The analysts said that the Nasdaq Biotechnology Index has bounced back to 2021 levels, outperforming the broader market. Key positives include strong data releases being rewarded, ongoing mergers and acquisitions by big pharma, better access to capital, and limited impact so far from drug pricing regulations. Innovation from China and shifts in global pharma spending add further upside potential.The analysts said they have refreshed their top picks for 2026 to include Revolution Medicines , Regenxbio , Krystal Biotech , and Immatics . \"We favor companies with near-term binary catalysts with derisking data to support a positive view,\" they said.BofA updated its price objectives for the top picks, raising Immatics to $17 from $14, Krystal Biotech to $272 from $255, Regenxbio to $","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","KRYS":"Krystal Biotech Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技","RGNX":"Regenxbio Inc","RVMD":"Revolution Medicines, Inc.","IMTX":"Immatics N.V."},"translate_title":"美国银行表示，生物技术行业有望在试验数据和制药交易的推动下实现增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1,"RGNX":1,"KRYS":1,"IMTX":1},"content_text":"The US biotechnology sector is poised for growth in 2026, with several companies having near-term catalysts and promising clinical trial readouts that could drive momentum, BofA Securities said in a note Tuesday.The analysts said that the Nasdaq Biotechnology Index has bounced back to 2021 levels, outperforming the broader market. Key positives include strong data releases being rewarded, ongoing mergers and acquisitions by big pharma, better access to capital, and limited impact so far from drug pricing regulations. Innovation from China and shifts in global pharma spending add further upside potential.The analysts said they have refreshed their top picks for 2026 to include Revolution Medicines (RVMD), Regenxbio (RGNX), Krystal Biotech (KRYS), and Immatics (IMTX). \"We favor companies with near-term binary catalysts with derisking data to support a positive view,\" they said.BofA updated its price objectives for the top picks, raising Immatics to $17 from $14, Krystal Biotech to $272 from $255, Regenxbio to $28 from $20, and Revolution Medicines to $98 from $82.Price: 79.86, Change: +1.53, Percent Change: +1.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}